Targepeutics announces a Phase I Small Business Innovation Research (SBIR) grant awarded to Dr Randy Schrecengost as Primary Investigator to support preliminary data demonstrating that GB13 can specifically target IL13Rα2-positive pediatric Diffuse Midline Glioma with H3K27 alterations tumor models. Along with Co-investigator Dr David Daniels at The Mayo Clinic, Rochester, MN, the research proposal is entitled ‘Development of GB13 for the Treatment of Pediatric Diffuse Intrinsic Pontine Glioma.’ Sil Lutkewitte, CEO of Targepeutics, stated “We are thrilled to receive this grant. The funding is helpful, of course, but also importantly we are excited to continue to work closely with Mayo Clinic on this project and we appreciate support and validation of our technology by the National Cancer Institute.” The research strategy combines GB13 treatment with clinically-relevant administration by convection enhanced delivery (CED) to assess efficacy in orthotopic animal models. Studies will also explore combination of GB13 with standard-of-care therapies as well as patient biopsy analysis of IL13Rα2 expression. Targepeutics expects the proposed work to be completed by 08/31/2023.